GovWire

Following announcement in May of the new scheme to replace the current EC Decision Reliance Procedure (ECDRP) on 1 January 2024, this guidance informs the sector on how they can use the scheme to apply for a medicine licence in the UK, following approval by trusted regulatory partners in Australia, Canada, the European Union, Japan, Switzerland, Singapore, and the United States.

This means that patients will have faster access to safe, effective cutting-edge medicines through our review and by leveraging the expert decision-making of our regulatory partners to streamline assessments of specific products, while maintaining the power of the MHRA as a sovereign regulator to scrutinise each application and the authority to reject them if the evidence provided is considered insufficiently robust.

At the time of the UKs exit from the European Union, the MHRA introduced temporary routes to market for European approved products in Great Britain, known as EU reliance routes, to ensure that patients could continue to have timely access to new treatments. These temporary routes will end on 31 December 2023. The MHRA is currently running a public consultation on their closure that will close on 27 September 2023.

Find out more

International Recognition Procedure

Follow us on Twitter: @MHRAgovuk

Follow us on LinkedIn: Medicines and Healthcare products Regulatory Agency

Notes to editors

1. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.? All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.

2. The MHRA is an executive agency of the Department of Health and Social Care.

3. For media enquiries, please contact the newsdesk@mhra.

   

   View the original news story